Logo image of JAGX

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

NASDAQ:JAGX - Nasdaq - US47010C8881 - Common Stock - Currency: USD

5.84  +0.08 (+1.39%)

Premarket: 5.8 -0.04 (-0.68%)

Fundamental Rating

2

Taking everything into account, JAGX scores 2 out of 10 in our fundamental rating. JAGX was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JAGX have multiple concerns. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JAGX had negative earnings in the past year.
In the past year JAGX has reported a negative cash flow from operations.
JAGX had negative earnings in each of the past 5 years.
In the past 5 years JAGX always reported negative operating cash flow.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -72.05%, JAGX is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
JAGX's Return On Equity of -393.98% is on the low side compared to the rest of the industry. JAGX is outperformed by 76.77% of its industry peers.
Industry RankSector Rank
ROA -72.05%
ROE -393.98%
ROIC N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

JAGX's Gross Margin of 83.27% is amongst the best of the industry. JAGX outperforms 87.88% of its industry peers.
JAGX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JAGX has been reduced compared to 1 year ago.
JAGX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for JAGX has been reduced compared to a year ago.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

JAGX has an Altman-Z score of -10.43. This is a bad value and indicates that JAGX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of JAGX (-10.43) is worse than 72.22% of its industry peers.
JAGX has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of JAGX (2.41) is worse than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF N/A
Altman-Z -10.43
ROIC/WACCN/A
WACC1.61%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

JAGX has a Current Ratio of 1.63. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.63, JAGX is not doing good in the industry: 67.68% of the companies in the same industry are doing better.
A Quick Ratio of 1.11 indicates that JAGX should not have too much problems paying its short term obligations.
JAGX has a worse Quick ratio (1.11) than 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.11
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

JAGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.98%, which is quite impressive.
Looking at the last year, JAGX shows a quite strong growth in Revenue. The Revenue has grown by 19.75% in the last year.
JAGX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.14% yearly.
EPS 1Y (TTM)74.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.16%
Revenue 1Y (TTM)19.75%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%50.65%

3.2 Future

Based on estimates for the next years, JAGX will show a very strong growth in Earnings Per Share. The EPS will grow by 37.61% on average per year.
The Revenue is expected to grow by 118.46% on average over the next years. This is a very strong growth
EPS Next Y77.42%
EPS Next 2Y37.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 -200M -400M -600M -800M -1B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JAGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as JAGX's earnings are expected to grow with 37.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.61%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

JAGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAGUAR HEALTH INC

NASDAQ:JAGX (5/20/2025, 8:07:03 PM)

Premarket: 5.8 -0.04 (-0.68%)

5.84

+0.08 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners2.14%
Inst Owner Change-99.82%
Ins Owners0.28%
Ins Owner Change0%
Market Cap3.91M
Analysts85.71
Price Target16.32 (179.45%)
Short Float %19.73%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.38%
Min EPS beat(2)56.56%
Max EPS beat(2)98.2%
EPS beat(4)2
Avg EPS beat(4)-51.02%
Min EPS beat(4)-230.06%
Max EPS beat(4)98.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.06%
Min Revenue beat(2)-22.63%
Max Revenue beat(2)8.52%
Revenue beat(4)1
Avg Revenue beat(4)-14.58%
Min Revenue beat(4)-22.63%
Max Revenue beat(4)8.52%
Revenue beat(8)3
Avg Revenue beat(8)-11.9%
Revenue beat(12)5
Avg Revenue beat(12)0.24%
Revenue beat(16)5
Avg Revenue beat(16)-20.33%
PT rev (1m)-89.33%
PT rev (3m)166.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2400%
EPS NY rev (1m)0%
EPS NY rev (3m)-2400%
Revenue NQ rev (1m)-14.27%
Revenue NQ rev (3m)-14.27%
Revenue NY rev (1m)-11.44%
Revenue NY rev (3m)-11.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-232.59
EYN/A
EPS(NY)-52.53
Fwd EYN/A
FCF(TTM)-44.2
FCFYN/A
OCF(TTM)-43.86
OCFYN/A
SpS17.45
BVpS14.58
TBVpS-13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.05%
ROE -393.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.27%
FCFM N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.16%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.11
Altman-Z -10.43
F-Score5
WACC1.61%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)19.49%
Cap/Sales(3y)5.33%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.16%
EPS Next Y77.42%
EPS Next 2Y37.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.75%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%50.65%
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%
EBIT growth 1Y9.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.61%
OCF growth 3YN/A
OCF growth 5YN/A